{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962621",
  "id": "02962621",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250627",
  "time": "0731",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250627/pdf/06l51mt4ngvpc7.pdf",
  "summary": "- **Director Interest Change**: Hartley Campbell Atkinson (Director) increased beneficial holdings in AFT Pharmaceuticals via inheritance (17,755 shares at zero consideration).  \n- **Total Holdings After Transaction**: 72,059,496 ordinary shares (jointly controlled via Atkinson Family Trust).  \n- **Closed Period Compliance**: Transaction did not occur during a prohibited trading period.  \n\nNo material impact on capital structure, valuation, or liquidity identified. Disclosure is routine.",
  "usage": {
    "prompt_tokens": 1382,
    "completion_tokens": 92,
    "total_tokens": 1474,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-26T21:47:07.670068"
}